PMV PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 220.64K shares, a 130.23% increase year-over-year.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 0.00 shares.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 242.84K shares, a 145.42% increase from fiscal 2024.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 98.95K shares, a 66.70% decline from fiscal 2023.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 297.14K shares, a 2.88% increase from fiscal 2022.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 288.81K shares, a 52.56% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | 220.64K shares derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-05-12 | 223.84K shares derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | 220.64K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | 242.84K shares 10-K · filed 2026-03-06 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 118.04K shares derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-06-30 | 3.20K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 118.04K shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 19.00K shares 10-Q · filed 2025-05-09 | |
| 2024-12-31 | 95.84K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | 98.95K shares 10-K · filed 2025-03-03 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | |
| 2023-12-31 | 200.78K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | 297.14K shares 10-K · filed 2024-02-29 |
| 2023-09-30 | 88.63K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 212.45K shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 4.30K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | 126.07K shares derived: sum of 4 quarters · filed 2023-08-09 |
| 2023-03-31 | 3.43K shares 10-Q · filed 2023-05-10 | 193.53K shares derived: sum of 4 quarters · filed 2023-05-10 |
| 2022-12-31 | 116.09K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | 288.81K shares 10-K · filed 2023-03-01 |
| 2022-09-30 | 2.25K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 243.72K shares derived: sum of 4 quarters · filed 2022-11-08 |
| 2022-06-30 | 71.76K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | 380.11K shares derived: sum of 4 quarters · filed 2022-08-09 |
| 2022-03-31 | 98.71K shares 10-Q · filed 2022-05-10 | 604.16K shares derived: sum of 4 quarters · filed 2022-05-10 |
| 2021-12-31 | 71.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | 608.80K shares 10-K · filed 2022-03-01 |
| 2021-09-30 | 138.64K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | |
| 2021-06-30 | 295.81K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | |
| 2021-03-31 | 103.35K shares 10-Q · filed 2021-05-14 | |
| 2020-12-31 | 4.07K shares 10-K · filed 2021-03-03 | |
| 2019-12-31 | 33.92K shares 10-K · filed 2021-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |